Mandatory testosterone screening takes effect for U.S. troops 30 and older, FDA panel the next event to watch
Mandatory testosterone deficiency screening for active-duty and reserve service members ages 30 and older took effect Wednesday under new Pentagon clinical guidelines. The Food and Drug Administration has an expert meeting on testosterone's medical use scheduled later this month. That session is the next concrete checkpoint as some endocrinologists contest the program's evidentiary basis.
Key takeaways
- Mandatory testosterone deficiency screening for active-duty and reserve U.S. service members ages 30 and older took effect Wednesday under new Pentagon clinical guidelines.
- Defense Secretary Pete Hegseth announced the program in July, saying it ensures troops have 'the right testosterone levels to operate at your absolute best.'
- Men 30 and older must submit to mandatory blood tests, while younger members are screened only on request or if a clinician flags warning signs, with voluntary hormone replacement therapy offered where clinically appropriate.
- Women are not routinely tested for testosterone but are screened for fatigue and disrupted menstrual cycles linked to hormonal dysregulation.
- The FDA has an expert panel meeting on testosterone's medical use scheduled later this month, the next public examination of the competing clinical-evidence claims.
Mandatory testosterone deficiency screening for active-duty and reserve service members ages 30 and older took effect Wednesday under new Pentagon clinical guidelines. The Food and Drug Administration has an expert meeting on testosterone's medical use scheduled later this month. That session is the next concrete checkpoint as some endocrinologists contest the program's evidentiary basis.
Defense Secretary Pete Hegseth announced the program in July, saying he was authorizing it to ensure troops carry "the right testosterone levels to operate at your absolute best." Under the rules now in force, men ages 30 and older submit to mandatory blood tests. Younger service members are screened only if they request testing or if a clinician flags warning signs. Those who test deficient may undergo further evaluation and, where clinically appropriate, may be offered voluntary hormone replacement therapy. The underlying biology: testosterone levels naturally begin to decline between ages 30 and 40.
Women are not subject to routine testosterone testing under the guidance, but they will be screened for fatigue and disrupted menstrual cycles, which the Pentagon connects to hormonal dysregulation and conditions called low-energy availability and relative energy deficiency in sport. Separate guidelines address when off-label testosterone prescriptions are appropriate for women, with particular attention to postmenopausal patients experiencing unusually low sexual desire. Testosterone use for performance enhancement without a physician's prescription remains prohibited across the force.
The readiness argument and where it meets resistance
The Pentagon's stated case is that standardized screening and treatment pathways for hormonal and energy-availability issues will lift readiness across the force. Some endocrinologists and other medical experts have raised concerns that broad testing risks producing unnecessary or potentially harmful treatment, and they argue the evidence that universal screening among service members actually improves readiness is lacking. Hegseth, presenting the program in July, also framed it in longer health terms, describing it as helping troops "thrive long after you take off the uniform."
The FDA's expert panel meeting later this month is where those competing claims about clinical evidence get their next public examination.
Related reading
Filed by the newsroom of MarketPR on September 3, 2026. Source: foxnews.com. Indicative figures are not investment advice.